OTS 167

Drug Profile

OTS 167

Alternative Names: OTS 167PO; OTS-167; OTSSP167

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OncoTherapy Science
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MELK protein inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Breast cancer; Solid tumours
  • Preclinical Renal cancer; Small cell lung cancer
  • Research Multiple myeloma

Most Recent Events

  • 29 May 2017 Phase-I clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02926690)
  • 06 Dec 2016 Early research in Multiple myeloma in Japan (unspecified route) before December 2016
  • 05 Oct 2016 OncoTherapy Science plans a phase I trial for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule) (NCT02926690)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top